FoodTech
Proto-Personalize
Personalized protein snacks tailored for GLP-1 medication users to manage protein intake effectively.
$12,000Est. Revenue
6 MonthsTimeline
Key Competitors
Novo NordiskEli Lilly
Business model
- Customer segments
- Consumers on GLP-1 medications
- Generations X, Y, Z, and Generation GLP-1
- Family units of GLP-1 users
- Value propositions
- High-protein, low-calorie, and high-fiber snacks tailored for GLP-1 users
- Convenient, ready-to-eat format for reduced cooking frequency
- Channels
- Online direct-to-consumer platform
- Partnerships with health and wellness stores
- Presence in major retail chains
- Customer relationships
- Personalized nutrition plans and subscription-based model offering regular deliveries of customized snacks.
- Revenue streams
- Sales of personalized protein snacks
- Subscription-based revenues from regular snack deliveries
- Key activities
- Product development and testing
- Data collection for personalization
- Marketing and customer acquisition
- Key resources
- Formulation experts for protein snacks
- Data analytics for personalization
- Manufacturing partnerships
- Key partnerships
- Pharmaceutical companies for cross-promotion
- Health care providers for user referrals
- Retail partnerships for distribution
- Cost structure
- R&D for product personalization
- Manufacturing and ingredient sourcing
- Marketing and distribution
Sources: sacra.com · medscape.com · extension.okstate.edu · dairyreporter.com · insightaceanalytic.com
Market research
- Market size & growth
- The global GLP-1 receptor agonist market is valued at USD 24.4 billion in 2023 and expected to grow at a CAGR of 9.7% from 2024 to 2032, driven by increasing demand for weight management solutions.
- Key competitors
- Novo Nordisk
- Eli Lilly
- Competitive advantages
- Focus on personalized, high-protein, nutrient-dense snacks specifically formulated for GLP-1 medication users, filling the niche for targeted dietary solutions.
- Market gaps
- A lack of personalized protein snacks catering specifically to the dietary requirements of GLP-1 users who are looking to maintain muscle mass while on medication.
- Barriers to entry
- Significant patent strategies by pharmaceutical giants and the challenge of establishing brand trust among GLP-1 users.
Sources: gminsights.com · grandviewresearch.com · i-mak.org · wsro.org · extension.okstate.edu